Summary & Overview
HCPCS J1250: Dobutamine Hydrochloride Injection, 250 mg
HCPCS Level II code J1250 denotes a 250 mg injection of dobutamine hydrochloride, a parenteral inotropic agent used to increase cardiac output in acute heart failure and related hemodynamic compromise. This code matters nationally because dobutamine is commonly used in acute care settings where precise billing for high-cost parenteral cardiac medications affects hospital and payer reimbursement and utilization oversight.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for dobutamine administration, the typical sites of service where J1250 is billed, and the payer landscape relevant to this HCPCS Level II drug code.
The publication provides benchmarks and billing guidance context (where available), summarizes common billing modifiers and practical considerations for claims involving parenteral inotropes, and outlines policy updates and reimbursement themes affecting injectable cardiac drugs. Data not available in the input is noted where applicable; the focus remains on national-level clinical and billing context for HCPCS Level II code J1250.
Billing Code Overview
HCPCS Level II code J1250 represents an injection of dobutamine hydrochloride, dosed per 250 mg. The code describes the pharmaceutical administration of dobutamine, a sympathomimetic agent commonly used to support cardiac output in patients with acute heart failure or cardiogenic shock.
Service Type: Intravenous medication administration of a cardiac inotrope.
Typical Site of Service: Hospital inpatient and hospital outpatient settings, including emergency departments and procedural areas where parenteral vasoactive medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J1250 is an adult hospitalized patient with acute decompensated heart failure or cardiogenic shock who requires inotropic support to improve cardiac output and organ perfusion. The clinician (cardiologist or intensivist) prescribes intravenous dobutamine after clinical assessment including vital signs, hemodynamic monitoring, and review of current medications. The medication is prepared by pharmacy and administered via continuous infusion through a central or peripheral IV line in an intensive care unit, step-down unit, or emergency department. Nursing monitors blood pressure, heart rate, telemetry, urine output, and signs of ischemia; dose adjustments are made based on response and side effects. The billing event for J1250 documents the injectable dobutamine hydrochloride product dispensed in 250 mg increments; documentation includes indication, dose, route, start and stop times, and any adverse reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Used when no other modifier is required for the claim |
11 |